Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication

Autor: Martin P. Grobusch, Caspar J. Hodiamont, Emile F.F. Jonker, Abraham Goorhuis, Leo G. Visser, Eric C. M. van Gorp, Rosanne W. Wieten, Adriëtte W. de Visser, Daan K.J. Pieren, Pieter P. A. M. van Thiel
Přispěvatelé: Infectious diseases, Graduate School, Medical Microbiology and Infection Prevention, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Virology
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Male
Antibodies
Viral
0302 clinical medicine
Medicine
030212 general & internal medicine
education.field_of_study
biology
Yellow Fever Vaccine
Vaccination
Middle Aged
Infectious Diseases
Fluorescent Antibody Technique
Direct
Molecular Medicine
Female
Antibody
Yellow fever
Immunosuppressive Agents
medicine.drug
Adult
030231 tropical medicine
Population
Yellow fever vaccine
03 medical and health sciences
Immunocompromised Host
Young Adult
Plaque reduction neutralization test
Immune system
SDG 3 - Good Health and Well-being
Neutralization Tests
Humans
Adverse effect
education
Plaque Reduction Neutralization Test (PRNT)
Immune-compromised
Aged
General Veterinary
General Immunology and Microbiology
business.industry
Public Health
Environmental and Occupational Health
Assay sensitivity
biochemical phenomena
metabolism
and nutrition
Virology
Antibodies
Neutralizing
Case-Control Studies
Immunology
biology.protein
bacteria
Indirect Fluorescence Assay (IFA)
business
Zdroj: Vaccine, 34(10), 1247-1251. Elsevier BV
Vaccine, 34(10), 1247-1251. ELSEVIER SCI LTD
Vaccine, 34(10), 1247-1251. Elsevier
ISSN: 0264-410X
Popis: Background The 17D-yellow fever (YF) vaccination is considered contraindicated in immune-compromised patients; however, accidental vaccination occurs. In this population, measuring the immune response is useful in clinical practice. Methods In this study we compare two antibody tests (the Immune Fluorescence Assay and the Plaque Reduction Neutralization Test) in a group of Dutch immune-compromised travellers with a median of 33 days (IQR [28–49]) after primary YF vaccination. Results We collected samples of 15 immune-compromised vaccinees vaccinated with the 17D yellow fever vaccine between 2004 and 2012. All samples measured in the plaque reduction neutralization test yielded positive results (>80% virus neutralization with a 1:10 serum dilution). Immune Fluorescence Assay sensitivity was 28% (95% CI [0.12–0.49]). No adverse events were reported. Conclusions All immune-compromised patients mounted an adequate response with protective levels of virus neutralizing antibodies to the 17-D YF vaccine. No adverse effects were reported. Compared to the plaque reduction neutralization test, the sensitivity of the Immune Fluorescence Assay test was low. Further research is needed to ascertain that 17D vaccination in immune-compromised patients is safe.
Databáze: OpenAIRE
Externí odkaz: